drugset / Trial / NCT05097443
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Although novel immunotherapies represented by anti-CD20 monoclonal antibodies and CAR-T cell therapies have significantly improved the prognosis of B-NHL patients, there are still nearly one-third of patients who are resistant to initial treatment or relapse after remission. R-CHOP combined with novel drugs was expected to improve the prognosis. Therefore, this study aimed to investigate the potential of Orelabrutinib combined with Rituximab and chemotherapy.
Timeline
- Start
- 2021-04-15
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Epirubicin | Small molecule | 15 mg/m2 | — |
| Subject | Etoposide | Small molecule | 50 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 3.5 g | — |
| Subject | Orelabrutinib | Small molecule | 150 mg | — |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 100 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Subject | Vindesine | Small molecule | 3 mg/m2 | — |